非肥胖型非酒精性脂肪性肝纤维化、肝硬化的发病机制及危险因素

陈艳珍; 陈成良; 洪宇; 王冠; 焦健

doi:10.3969/j.issn.1001-5256.2018.10.037

非肥胖型非酒精性脂肪性肝纤维化、肝硬化的发病机制及危险因素

DOI: 10.3969/j.issn.1001-5256.2018.10.037

吉林大学中日联谊医院消化内科

详细信息

中图分类号: R575
计量
- 文章访问数: 2146
- HTML全文浏览量: 16
- PDF下载量: 487
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-25
- 出版日期: 2018-10-20

Research advances in the pathogenesis and risk factors of non-obese non-alcoholic fatty liver fibrosis and liver cirrhosis

Department of Gastroenterology, China-Japan Union Hospital of Jilin University

摘要

摘要: 目前,非酒精性脂肪性肝病(NAFLD)已经成为全球慢性肝病的主要病因,是隐源性肝硬化的常见致病因素。临床上,NAFLD患者多见于肥胖群体,但非肥胖人群中NAFLD亦不罕见,尤其是亚洲人群。非肥胖型NAFLD与肥胖型NAFLD代谢谱相当,但最近多项研究显示与肥胖型NAFLD相比,非肥胖型肝纤维化、肝硬化有其独特的特点。回顾了近年来非肥胖型非酒精性脂肪性肝纤维化、肝硬化的发病机制及危险因素,以期更好地了解该病的预防、诊断和治疗。
- 非酒精性脂肪性肝病 /
- 肝硬化 /
- 综述
Abstract: At present, non-alcoholic fatty liver disease ( NAFLD) has become the major cause of chronic liver disease in the world and is considered a common pathogenic factor of cryptogenic cirrhosis. In clinical practice, NAFLD is commonly seen in obese patients; however, it is not rare among non-obese individuals, especially in the Asian population. Non-obese NAFLD patients have similar metabolic profiles to obese NAFLD patients, but many studies have revealed that compared with obese NAFLD, non-obese liver fibrosis and liver cirrhosis have unique features. This article reviews the research advances in the pathogenesis and risk factors of non-obese non-alcoholic fatty liver fibrosis and liver cirrhosis in recent years, in order to gain a better understanding of the prevention, diagnosis, and treatment of this disease.
- non-alcoholic fatty liver /
- liver cirrhosis /
- review

HTML全文

参考文献(50)

[1]KIM D, KIM WR.Nonobese fatty liver disease[J].Clin Gastroenterol Hepatol, 2017, 15 (4) :474-485.

[2]WEI JL, LEUNG JC, LOONG TC, et al.Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients:A population study using proton-magnetic resonance spectroscopy[J].Am J Gastroenterol, 2015, 110 (9) :1306-1314.

[3]CRUZ ACD, BUGIANESI E, GEORGE J, et al.379 characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease[J].Gastroenterology, 2014, 146 (5) :s909.

[4]CUI J, CHEN CH, LO MT, et al.Shared genetic effects between hepatic steatosis and fibrosis:A prospective twin study[J].Hepatology, 2016, 4 (5) :1547-1558.

[5]KWON YM, OH SW, HWANG SS, et al.Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults[J].Am J Gastroenterol, 2012, 107 (12) :1852-1858.

[6]BADOUD F, PERREAULT M, ZULYNIAK MA, et al.Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals[J].FASEB J, 2015, 29 (3) :748-758.

[7]KIM NH, KIM JH, KIM YJ, et al.Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects[J].Liver Int, 2014, 34 (4) :604-611.

[8]AMPUERO J, RANCHAL I, GALLEGO-DURN R, et al.Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients[J].J Gastroenterol Hepatol, 2016, 31 (9) :1611-1618.

[9]ALKHOURI N, CARTER-KENT C, FELDSTEIN AE.Apoptosis in nonalcoholic fatty liver disease:Diagnostic and therapeutic implications[J].Expert Rev Gastroenterol Hepatol, 2011, 5 (2) :201-212.

[10]MARCHESINI G, BRIZI M, BIANCHI G, et al.Nonalcoholic fatty liver disease:A feature of the metabolic syndrome[J].Diabetes, 2001, 50 (8) :1844-1850.

[11]BUGIANESI E, GASTALDELLI A, VANNI E, et al.Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease:Sites and mechanisms[J].Diabetologia, 2005, 48 (4) :634-642.

[12]GASTALDELLI A, HARRISON SA, BELFORT-AGUILAR R, et al.Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis[J].Hepatology, 2009, 50 (4) :1087-1093.

[13]FELDMAN A, EDER SK, FELDER TK, et al.Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver[J].Am J Gastroenterol, 2017, 112 (1) :102-110.

[14]KORENBLAT KM, FABBRINI E, MOHAMMED BS, et al.Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects[J].Gastroenterology, 2008, 134 (5) :1369-1375.

[15]TSOCHATZIS E, PAPATHEODORIDIS GV, ARCHIMANDRITISAJ.The evolving role of leptin and adiponectin in chronic liver diseases[J].Am J Gastroenterol, 2006, 101 (11) :2629-2640.

[16]STOJSAVLJEVIC'S, GOMERCˇIC'PALCˇIC'M, VIROVIC'JUKIC'L, et al.Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease[J].World JGastroenterol, 2014, 20 (48) :18070-18091.

[17]JARRAR MH, BARANOVA A, COLLANTES R, et al.Adipokines and cytokines in non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther, 2008, 27 (5) :412-421.

[18]KUMAR R, PRAKASH S, CHHABRA S, et al.Association of pro-inflammatory cytokines, adipokines&oxidative stress with insulin resistance&non-alcoholic fatty liver disease[J].Indian J Med Res, 2012, 136 (2) :229-236.

[19]MOTOSHIMA H, WU X, SINHA MK, et al.Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes:Effects of insulin and rosiglitazone[J].J Clin Endocrinol Metab, 2002, 87 (12) :5662-5667.

[20]KAPIL S, DUSEJA A, SHARMA BK, et al.Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol, 2016, 31 (1) :213-221.

[21]MACHADO MV, CORTEZ-PINTO H.No need for a large belly to have NASH[J].J Hepatol, 2011, 54 (6) :1090-1093.

[22]van der POORTEN D, MILNER KL, HUI J, et al.Visceral fat:A key mediator of steatohepatitis in metabolic liver disease[J].Hepatology, 2008, 48 (2) :449-457.

[23]RUDERMAN N, CHISHOLM D, PI-SUNYER X, et al.The metabolically obese, normal-weight individual revisited[J].Diabetes, 1998, 47 (5) :699-713.

[24]FRACANZANI AL, VALENTI L, BUGIANESI E, et al.Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity[J].J Hepatol, 2011, 54 (6) :1244-1249.

[25]HA Y, SEO N, SHIM JH, et al.Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians:Acase-control study[J].J Gastroenterol Hepatol, 2015, 30 (11) :1666-1672.

[26]LI Q, WANG N, HAN B, et al.Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men[J].Nutr Metab (Lond) , 2015, 12 (1) :63.

[27]MENG K, LEE CH, SAREMI F.Metabolic syndrome and ectopic fat deposition:What can CT and MR provide?[J].Acad Radiol, 2010, 17 (10) :1302-1312.

[28]YIM JY, KIM D, LIM SH, et al.Sagittal abdominal diameter is a strong anthropometric measure of visceral adipose tissue in the Asian general population[J].Diabetes Care, 2010, 33 (12) :2665-2670.

[29]NISHIOJI K, SUMIDA Y, KAMAGUCHI M, et al.Prevalence of and risk factors for non-alcoholic fatty liver disease in a nonobese Japanese population, 2011-2012[J].J Gastroenterol, 2015, 50 (1) :95-108.

[30]OMAGARI K, KADOKAWA Y, MASUDA J, et al.Fatty liver in non-alcoholic non-overweight Japanese adults:Incidence and clinical characteristics[J].J Gastroenterol Hepatol, 2002, 17 (10) :1098-1105.

[31]SHIMIZU I, KOHNO N, TAMAKI K, et al.Female hepatology:Favorable role of estrogen in chronic liver disease with hepatitis Bvirus infection[J].World J Gastroenterol, 2007, 13 (32) :4295-4305.

[32]WONG RJ, LIU B, BHUKET T.Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US:A cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey[J].Aliment Pharmacol Ther, 2017, 46 (10) :974-980.

[33]SINGAL AG, MANJUNATH H, YOPP AC, et al.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma:A meta-analysis[J].Am J Gastroenterol, 2014, 109 (3) :325-334.

[34]AN BQ, XIN YN, LU LL, et al.Effect of PNPLA3 I148M mutation on expression of TGF-β1 in rat hepatic stellate cells[J].J Clin Hepatol, 2016, 32 (4) :769-771. (in Chinese) 安佰全, 辛永宁, 芦琳琳, 等.PNPLA3 I148M基因突变对大鼠肝星状细胞转化生长因子β1表达的影响[J].临床肝胆病杂志, 2016, 32 (4) :769-771.

[35]ZHANG ZL, HUANG YS, FAN YD, et al.Effect of Xuezhikang on hepatitis and oxidative stress in rats with nonalcoholic fatty liver disease[J].Clin J Med Offic, 2018, 46 (6) :605-609. (in Chinese) 张子龙, 黄樱硕, 范煜东, 等.血脂康对非酒精性脂肪性肝病大鼠肝炎症及氧化应激影响[J].临床军医杂志, 2018, 46 (6) :605-609.

[36]PETTA S, GRIMAUDO S, CAMMC, et al.IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease[J].J Hepatol, 2012, 56 (6) :1356-1362.

[37]ONIKI K, SARUWATARI J, IZUKA T, et al.Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects[J].PLo SOne, 2015, 10 (7) :e0132640.

[38]NISHIOJI K, MOCHIZUKI N, KOBAYASHI M, et al.The impact of PNPLA3 rs738409 genetic polymorphism and weight gain≥10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals[J].PLo S One, 2015, 10 (10) :e0140427.

[39]LALLUKKA S, SEVASTIANOVA K, PERTTILJ, et al.Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3[J].Diabetologia, 2013, 56 (4) :886-892.

[40]BING H, SHEN JH, LI YL.The relationship between TM6SF2rs58542926 E167K single nucleotide polymorphisms and the susceptibility of liver cirrhosis and hepatocellular carcinoma[J].Chin J Gastroenterol Hepatol, 2017, 26 (4) :369-371. (in Chinese) 邴浩, 沈剑华, 李异玲.TM6SF2 rs58542926 E167K单核苷酸多态性与肝硬化、肝细胞癌易感性的关系[J].胃肠病学和肝病学杂志, 2017, 26 (4) :369-371.

[41]MUSSO G, CASSADER M, BO S, et al.Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism[J].Diabetes, 2013, 62 (4) :1109-1120.

[42]CABALLERO F, FERNáNDEZ A, DE LACY AM, et al.Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH[J].J Hepatol, 2009, 50 (4) :789-796.

[43]ADAMS LA, MARSH JA, AYONRINDE OT, et al.Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity[J].J Gastroenterol Hepatol, 2012, 27 (9) :1520-1527.

[44]PETTA S, VALENTI L, TUTTOLOMONDO A, et al.Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease[J].Hepatology, 2017, 66 (6) :1885-1893.

[45]HEBBARD L, GEORGE J.Animal models of nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol, 2011, 8 (1) :35-44.

[46]FERDER L, FERDER MD, INSERRA F.The role of high-fructose corn syrup in metabolic syndrome and hypertension[J].Curr Hypertens Rep, 2010, 12 (2) :105-112.

[47]ABID A, TAHA O, NSEIR W, et al.Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome[J].J Hepatol, 2009, 51 (5) :918-924.

[48]ENJOJI M, YASUTAKE K, KOHJIMA M, et al.Nutrition and nonalcoholic fatty liver disease:The significance of cholesterol[J].Int J Hepatol, 2012, 2012:925807.

[49]YASUTAKE K, NAKAMUTA M, SHIMA Y, et al.Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease:The significance of dietary cholesterol[J].Scand J Gastroenterol, 2009, 44 (4) :471-477.

[50]KNEEMAN JM, MISDRAJI J, COREY KE.Secondary causes of nonalcoholic fatty liver disease[J].Therap Adv Gastroenterol, 2012, 5 (3) :199-207.

施引文献

资源附件(0)

访问统计